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Abstract: 
 
 
The paracaspase MALT1 is an Arg-specific protease that cleaves multiple substrates 
to promote lymphocyte proliferation and survival.  The catalytic activity of MALT1 is 
normally tightly regulated by antigen receptor triggering, which promotes MALT1 
activation by its inducible monoubiquitination-dependent dimerization.  Constitutive 
MALT1 activity is a hallmark of specific subsets of B-cell lymphomas, which are 
characterized by chromosomal translocations or point mutations that activate MALT1 
or its upstream regulators.  Recent findings suggest that such lymphomas may be 
sensitive to treatment with MALT1 inhibitors.  Here we review recent progress in the 
understanding of MALT1 function and regulation, and the development of small 
molecule MALT1 inhibitors for therapeutic applications. 
 
 
Introduction  
B-cell malignancies can arise from B-cell precursors in the bone marrow, giving rise 
to B-cell leukemias, or from tissue B-cells, giving rise to localized tumors called B-cell 
lymphomas.  The molecular mechanisms underlying the development of B-cell 
malignancies have been intensively studied [1,2].  During their development, B-cells 
undergo multiple gene rearrangements that are required for the generation of a 
diverse and high affinity antibody repertoire.  As a consequence, B-cell malignancies 
can frequently arise from defective gene rearrangements that lead to oncogenic gene 
translocations. These can lead to abnormally high expression of translocated proto-
oncogenes or to the generation of novel fusion proteins with oncogenic properties.  
Here, we will focus on lymphoma types with aberrant expression or activity of the 
proto-oncogene and protease MALT1, and the mechanisms underlying MALT1-
dependent cellular transformation.  We will also summarize recent progress in the 
development of techniques to monitor MALT1 activity, which have allowed the 
identification of first generation MALT1 inhibitors with promising anti-lymphoma 
effects in preclinical animal studies. 
 
Structure and function of MALT1: scaffold and protease activities 
The gene encoding MALT1 was originally discovered and named after a 
chromosomal translocation associated with an aggressive form of B-cell lymphoma 
arising from the mucosa-associated lymphoid tissue (MALT) of the gastric mucosa 
[3].  Subsequent bioinformatic and biochemical approaches have characterized 
MALT1 as a protein with a central protease-like domain that shares homology with 
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caspases; MALT1 has therefore also been named paracaspase [4]. Additional 
structural features of MALT1 are an N-terminal death domain of unknown function, 
which is followed by two immunoglobulin-like domains, and a C-terminal region 
containing a third Ig-like domain and a structurally undefined extension [5,6] (Figure 
1A).  These different domains define the molecular function of MALT1, which 
comprises both scaffold and enzymatic (proteolytic) activities.  The N-terminal 
immunoglobulin domains are required for MALT1’s binding to the adaptor protein 
BCL10 [4,5].  Upon antigen receptor triggering, BCL10 and MALT1 are recruited to 
the upstream signaling protein CARMA1 [7-9].  The resulting CARMA1-BCL10-
MALT1 (CBM) complex promotes the MALT1-dependent recruitment of the ubiquitin 
ligase TRAF6 via binding sites situated in the C-terminal region [10] and in the 
second Ig domain of MALT1 [11] (Figure 1, A and B).  This induces the rapid but 
transient activation of the proliferation-promoting transcription factor NF-κB by the 
classical (canonical) NF-κB pathway [10,12] (Figure 1B).  Another consequence of 
CBM complex formation is the activation of the protease activity of MALT1, which 
assures long-lasting NF-κB activation by the cleavage of the NF-κB1 inhibitors RelB 
and A20 (see below) [13-15].  Several other, highly relevant aspects of lymphocyte 
activation and proliferation are controlled by the cleavage of a growing list of 
additional MALT1 substrates (Figure 1B and Table 1).  Cleavage of the 
deubiquitinating enzyme CYLD has been proposed to promote antigen receptor-
induced activation of the AP-1 family of transcription factors, and the expression of 
pro-inflammatory genes such as IL-2 and IL-8 in activated T-lymphocytes [16].  
MALT1 further controls gene expression at a post-transcriptional level, by cleaving 
the RNAse Regnase-1 (also known as MCPIP-1 or Zc3h12a) [17].  MALT1-
dependent cleavage of its binding partner BCL10 has been shown to promote 
lymphocyte adhesion by beta1 integrins [13].  Recently, the protease activity of 
MALT1 was shown to be required for TCR-induced glutamine uptake and activation 
of the mTORC1 complex, most likely by the regulation of the amino acid transporter 
ASCT2, but the substrate responsible for this function remains unknown [18] (Figure 
1B). Collectively, these findings suggest that MALT1 controls B- and T-cell activation 
by the cleavage of a multitude of (known and yet to be identified) substrates.  
Consistent with this idea, mice expressing a catalytically inactive mutant of MALT1 
show severe defects in adaptive immune responses [19]. 
 
MALT1-dependent NF-κB activation and lymphomagenesis 
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The molecular function of MALT1 in NF-κB activation, and the role of constitutive NF-
κB activation in lymphomagenesis have been intensively studied.  Heterodimers of 
the NF-κB1 subtype (p50-RelA or p50-c-Rel dimers) act as major drivers of cellular 
proliferation and survival as they control the expression of numerous genes that 
inhibit cell death and actively promote proliferation [20].  MALT1 has been shown to 
promote NF-κB1 activation by two distinct means that are outlined in Figure 1B.  As 
a scaffold protein, MALT1 promotes activation of the IKK complex by the recruitment 
of the ubiquitin ligase TRAF6 [10], and potentially by the recruitment of the linear 
ubiquitin chain assembly complex (LUBAC) [21,22].  IKK-mediated phosphorylation 
of the NF-κB inhibitor IκBα then triggers its proteasomal degradation, and allows NF-
κB1 complexes to enter the nucleus and initiate transcription.  This so-called 
canonical, IKK-dependent NF-κB1 activation is rapid but transient, since the 
transcription and thus the re-synthesis of IκBα is rapidly induced by NF-κB1 as part 
of a negative feedback mechanism [20].  A second, IKK-independent means by 
which MALT1 induces NF-κB1 activation is via its protease activity [13-15,23].  Upon 
its activation, MALT1 cleaves RelB and A20, two proteins that inhibit NF-κB1 
activation in lymphocytes [14,15].  In lymphocytes, RelB inhibits canonical NF-κB 
activation by forming transcriptionally inactive complexes with the NF-κB1 subunit 
RelA and c-Rel [15,24].  MALT1-dependent RelB cleavage leads to proteasomal 
degradation of RelB, thereby lowering RelB levels for many hours [15].  MALT1-
dependent cleavage of A20, on the other hand, most likely contributes to weaken 
A20’s inhibitory role in NF-κB1 activation [14].  MALT1 also cleaves itself after Arg 
149 (Table 1), and this autoprocessing controls an essential step of NF-κB1 
activation downstream of its nuclear accumulation, by mechanisms that remain to be 
explored [25].  Collectively, these observations show that the protease activity of 
MALT1 massively increases the amplitude and duration of the NF-κB1 response.   
 
Lymphomas with constitutive MALT1 activity 
In activated lymphocytes, NF-κB activation by MALT1 requires the physical 
recruitment of MALT1 into a CARMA1-BCL10-MALT1 (CBM) signaling complex that 
is transiently formed upon triggering of the antigen receptor on the surface of 
lymphocytes [26].  Recently, B-cell lymphomas with constitutive, antigen-independent 
MALT1 activity have been described (Figure 2) [27-30].  These include diffuse large 
B-cell lymphoma (DLBCL), with a prevalence of roughly 30-40 % the most common 
form of lymphoma, mantle cell lymphoma (MCL, frequency 7-10 %) and mucosa-
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associated lymphoid tissue lymphoma (MALT, frequency 9 %) (for a recent review, 
see [31]).   
In diffuse large B-cell lymphomas of the activated B-cell (ABC) subtype, 
several mutations have been described that trigger constitutive MALT1 protease 
activity.  Mutations in the B-cell receptor (BCR)-associated CD79B chain have been 
associated with chronic BCR signaling [32].  Mutation of a critical tyrosine in the 
immunoreceptor tyrosine-based activation (ITAM) motif of CD79B inhibits Lyn kinase 
activity and thus prevents activation-induced down-regulation of the BCR, thereby 
enhancing CBM complex formation (Figure 2) [32]. On the other hand, potentially 
oncogenic mutations of CARMA1 increase CBM complex formation and thus the 
activation of downstream signaling pathways [33]. In non-stimulated lymphocytes, 
the coiled-coil domain of CARMA1 interacts with the CARD domain in an intra-
molecular fashion, and thereby keeps CARMA1 in an inactive state [34]. Mutations of 
the coiled-coil domain, which can be found in roughly 10 % of ABC DLBCLs patient 
samples, have been shown to favor the active conformation and induce CARMA1 
oligomerization and MALT1 protease activity [27,33] (Figure 2). The growth of ABC 
DLBCL cell lines is strongly reduced by interfering with MALT1 upstream regulators 
such as PKC, CARMA1 and BCL10, but also by MALT1 protease inhibition, 
indicating a central role for MALT1 protease activity in the maintenance of this 
aggressive lymphoma subtype [27,28,33,35].    
A second type of lymphoma with constitutive MALT1 activity is the MALT 
lymphoma [3].  Low-grade MALT lymphomas are typically driven by a chronic 
inflammatory infection with H. pylori, and can be treated by antibiotic treatment.  
More aggressive, advanced stages of these lymphomas are characterized by 
antigen-independent constitutive NF-κB activation [3].  A large proportion of these is 
characterized by the presence of a chromosomal translocation (t(11;18)(q21;q21)) 
encoding the oncogenic IAP2-MALT1 fusion protein that activates both, NF-κB1 and 
NF-κB2 (p52-RelB) complexes [4-6,29,36-38] (Figure 2).  The IAP2-MALT1 fusion 
recruits TRAF6 to promote canonical, IKK-dependent NF-κB1 activation [11].  In 
addition, the IAP2-MALT1 is constitutively activated by monoubiquitination [39], and 
cleaves natural MALT1 substrates such as A20 [14] to promote NF-κB1 activation.  
Interestingly, the IAP2-MALT1 fusion protein specifically triggers NF-κB2 activation 
by the cleavage of the Ser/Thr kinase NIK, which is not a natural substrate of MALT1 
[29] (Figure 2). NIK normally has a very short half-life, but its IAP2-MALT1-
dependent cleavage generates a stable NIK fragment, which promotes the activation 
of the NF-κB2 pathway through phosphorylation and subsequent proteolytic 
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maturation of the NF-κB2 precursor p100 into p52 [29].  This seems to be a unique 
feature of MALT lymphomas presenting the IAP2-MALT1 fusion, since NF-κB2 is not 
normally activated by MALT1.  The above-described IAP2-MALT1 fusion is present 
in roughly 50 % of gastrointestinal MALT lymphomas [40,41].  An alternative 
chromosomal translocation of the MALT1 gene towards the Ig enhancer element, 
t(14;18)(q32; q21), is prevalent in non-gastrointestinal MALT lymphomas, such as 
those of the liver, skin, eye and salivary gland [42,43].  This translocation leads to 
strongly upregulated expression of the translocated MALT1 gene [44], and thereby 
most likely to oligomerization-induced MALT1 activation.  A small proportion of MALT 
lymphomas with a chromosomal translocation of the BCL10 gene towards the Ig 
enhancer element, t(1;14)(p22;q32), has also been described [45,46].  In these 
lymphomas, MALT1 activation is most likely driven by BCL10 overexpression-
induced oligomerization of endogenous MALT1 [3,10].   
A recently identified third type of lymphoma that frequently presents with 
constitutive MALT1 activity is mantle cell lymphoma [30].  Two subgroups of MCL 
have been identified that can be classified by their sensitivity to BCR signaling 
inhibitors [30].  The BCR-dependent, PKC-sensitive MCLs show constitutive RelB 
cleavage, indicating deregulated MALT1 protease activity.  In contrast, BCR-
independent MCLs seem to depend on alternative NF-κB signaling.  Thus far, 
however, it is unclear which genetic alterations underlie MALT1 activation in MCL.  
 
Techniques to monitor MALT1 activity  
Several different techniques can be used to assess MALT1 activity; these have been 
described in detail elsewhere [47]. The detection of cleaved MALT1 substrate 
fragments in cell or tissue lysates by Western Blot (WB) seems to be the most 
straightforward way to monitor MALT1 protease activity (Figure 3A). However, 
detection of the cleavage fragments can be difficult for several reasons. First, 
cleavage may result in only a minimal size shift of the full-length substrate, as 
described for BCL10, a 233 aa protein that is cleaved after aa 228 [13]. Second, only 
a minor proportion of the substrate may be cleaved upon MALT1 activation; this is 
the case for A20 [14]. Third, the cleavage fragment may have a short half-life and 
therefore be detectable only upon addition of proteasome inhibitors, as described for 
RelB [15].  Additionally, the amount of protein available from biopsies may be 
limiting, and the screening of large sample numbers by WB is not convenient.  To 
assess MALT1 activity quantitatively in large sample numbers, fluorescence-based in 
vitro cleavage assays have been established that are amenable to high-throughput 
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screening [13,14,48].  In these assays, recombinant or immunoprecipitated MALT1 is 
incubated with an aminomethlycoumarin (amc)-conjugated MALT1 tetrapeptide 
substrate; proteolytic removal of the peptide from the amc fluorophore will result in a 
measurable shift in fluorescence emission (Figure 3B).  A reported optimal substrate 
in this assay is the LVSR-amc peptide [48], which contains the sequence of the RelB 
cleavage site [15] (Table 1).  To screen for MALT1 activity in intact cells, a FRET-
based reporter assay has been developed [39]. The reporter contains the fluorescent 
proteins YFP and CFP, which were fused by a short linker containing a MALT1 
cleavage recognition site.  The close proximity of YFP and CFP results in FRET, 
consequently MALT1-mediated cleavage leads to a loss of the FRET signal, which 
can be quantified by flow cytometry [39] (Figure 3C).  
 
Mechanisms of MALT1 protease activation 
The molecular events that control MALT1 activation upon antigen receptor triggering 
are under intense investigation.  Crystallographic evidence supports the idea of a 
major conformational switch between the inactive and the active form of MALT1.  
The inactive state is characterized by a conformation in which the catalytic dyad 
between C464 and H415 cannot be formed properly and substrate binding to the 
recognition site is restricted [49]. The structure of substrate-bound MALT1 (which is 
thought to mimic the active conformation) clearly differs from the inactive 
conformation in the position of key elements like the catalytic dyad or the 
autoinhibitory Ig3 domain [49,50]. 
The mechanism controlling the switch from the inactive to the active 
conformation in vivo is not well understood, but probably requires a combination of 
induced proximity, substrate binding and a monoubiquitination-dependent 
stabilization of the active dimer conformation.  Induced proximity, which is also a 
requirement for the activation of initiator caspases, is most likely achieved by the 
CARMA1- and BCL10 dependent oligomerization of MALT1, which may occur on 
cytoplasmic filamentous BCL10 structures [51].  The resulting assembly of MALT1 
dimers may allow for a conformational change that can be transmitted by an 
interaction between E549 in the dimerization interface and the R465 residue that 
neighbors the active site C464 residue [49,52].  Substrate binding to the active site 
may induce additional structural rearrangements required for full activation [49].  
Interestingly, both MALT1 and caspases undergo autoprocessing, but the purpose 
and sites of processing are very distinct.  MALT1 autoprocessing is not required for 
its protease activity, and in contrast to caspases, which are processed within the 
protease domain, MALT1 autoprocessing occurs outside the protease domain, within 
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the first Ig domain [25].  The only known post-translational modification of MALT1 
that is required for MALT1 activation is a monoubiquitination at K644 within the Ig3 
domain [39]. Addition of a single ubiquitin moiety is sufficient to activate MALT1 
protease activity, and to favor the dimerization of a recombinant purified MALT1 
construct in vitro [39]. Monoubiquitination may trigger the active conformation of the 
protease, for example by inactivating the autoinhibitory Ig3 domain, or it may 
promote an intermolecular interaction between two MALT1 molecules and thereby 
stabilize active dimers (as proposed in Figure 3D).  
 
Development of therapeutic MALT1 inhibitors 
The first described cell permeable MALT1 inhibitor was the peptide-based compound 
VRPR-fmk [13], which was designed based on an optimal tetrapeptide substrate of a 
protease of the metacaspase family [53], a group of caspase- and 
paracaspase/MALT1-related proteases expressed in plants, fungi and parasites [4].  
Incubation of T cells or cells derived from ABC-DLBCLs with VRPR-fmk efficiently 
inhibited MALT1 protease activity; inhibitor treatment resulted in reduced IL-2 
production or induction of cytotoxicity, respectively [13,27,28].  The recent 
development of techniques used to assess MALT1 activity [13,14,48] has opened the 
way to the screening and characterization of small molecule MALT1 inhibitors for 
therapeutic applications.  By the use of the fluorescence-based MALT1 in vitro 
cleavage assay, two groups reported identification of small molecule MALT1 
inhibitors from chemical libraries [54,55], which inhibit MALT1 by distinct means 
(Figure 3D).  Interestingly, three phenothiazine derivatives proved to function as 
MALT1 inhibitors [54].  Amongst these were Mepazine and Thioridazine, compounds 
that have been used in the past as anti-anxiety/anti-psychotic drugs with antagonistic 
effects on dopamine receptors [56].  The phenothiazine derivatives are reversible, 
non-competitive MALT1 inhibitors [54], which do not bind the catalytic site but rather 
an allosteric pocket on MALT1 that is situated between the caspase domain and the 
Ig3 domain [54,57].  Binding to this hydrophobic pocket most likely prevents the 
conformational switch of MALT1 into the enzymatically active conformation [57].  In 
contrast, another newly identified inhibitor, named MI-2, bound to the active site of 
the protease and acted as a suicide inhibitor [55].  Crystallographic data for the 
protease domain of MALT1 in its inactive and active form, and bound to competitive 
or allosteric inhibitors are now available [49,50,57].  Based on these, additional, 
structure-based inhibitors can likely be developed with the help of in silico 
approaches.  MALT1 monoubiquitination on Lysine 644 within the Ig3 domain favors 
the dimerization of MALT1, most likely via a conformational change that depends on 
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an intra- or intermolecular ubiquitin-MALT1 interaction [39]; both the unknown 
ubiquitin ligase as well as the unidentified ubiquitin-MALT1 interaction surfaces may 
thus represent additional targets for MALT1 inhibition that remain to be explored 
(Figure 3D).   
So far, first encouraging results have been obtained for the application of 
MALT1 inhibitors in the treatment of ABC DLBCL.  Phenothiazine derivatives, as well 
as MI-2, were able to efficiently slow down the growth of a human ABC DLBCL cell 
line in a mouse xenograft model, demonstrating potential anti-lymphoma activity in 
this preclinical model.  Additional potential fields of applications for MALT1 inhibitors 
are autoimmune diseases, which are characterized by excessive lymphocyte 
activation.  Indeed, MALT1 inhibition by mepazine was recently shown to efficiently 
attenuate the onset and progression of experimental autoimmune encephalomyelitis 
(EAE), a murine model of multiple sclerosis [58].  These findings are consistent with 
the observation that MALT1-deficient mice and mice expressing a catalytically 
inactive mutant of MALT1 are fully protected from EAE induction [19,59,60].  Further 
investigations are needed to optimize the lead substances with respect to inhibitory 
capacities and to evaluate their clinical safety. If safe and efficient MALT1 inhibitors 
can be developed, these should be of interest not only for the treatment of ABC 
DLBCL, but also for MALT and mantle cell lymphomas and for other, yet 
undiscovered malignancies or inflammatory diseases with constitutive MALT1 
activity.   
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Figure Legends 
 
Figure 1 : Structure and function of the human paracaspase MALT1. 
(A) Domain structure of MALT1, including the death domain (DD), the 
immunoglobulin-like (Ig) domains and the caspase-like domain. Indicated above are 
scaffold functions that include domains or motifs required for binding to BCL10 and 
TRAF6, as well as the presence of multiple C-terminal sites for K63-linked 
polyubiquitination, which mediate recruitment of NEMO/IKKγ. Indicated below are 
residues controlling the protease function, including the active site residues (C464 
and H415) and the monoubiquitination site (K644) required for MALT1 activation. 
The position of a recently identified autoprocessing site (R149) is also indicated.  
(B) Overview of MALT1-dependent lymphocyte activation via scaffold and protease 
functions.  As a scaffold, MALT1 promotes NF-κB activation via TRAF6 and the IKK 
complex, which phosphorylates the NF-κB inhibitor IκB to target it for proteasomal 
degradation. The protease activity of MALT1 controls NF-κB activation, AP-1 
activation, mRNA stability, cellular adhesion and mTORC1 activation by the cleavage 
of various substrates.   
 
Table : MALT1 substrates and the biological consequences of their cleavage. 
Table summarizing known MALT1 substrates (with domain structure and cleavage 
site) and the consequences of their cleavage.  Domain structure and cleavage sites 
are for the human proteins.  Abbreviated domain names: cytoskeleton-associated 
protein-Gly (CAP), caspase recruitment domain (CARD), death domain (DD), 
immunoglobulin-like (Ig), leucine zipper (LZ), ovarian tumor (OTU), Rel homolgy 
domain (RHD), transactivation domain (TAD), ubiquitin association (UBA), ubiquitin-
specific protease (USP), Zinc Finger (ZF).  
 
Figure 2 : MALT1 protease activation by genetic aberrations in lymphoma cells   
Scheme summarizing oncogenic mutations that promote MALT1 protease activity in 
ABC DLBCL (upper panels) and MALT lymphoma (lower left panel). CD79 and 
CARMA1 mutations that were found in ABC DLBCLs activate the protease MALT1 
by different mechanisms. Mutations in the ITAM motif of CD79 decrease Lyn kinase 
activity and thus prevent signal-induced downregulation of the BCR. Coiled-coil 
mutations in CARMA1 weaken the intramolecular interaction between the coiled-coil 
and CARD domain and thereby promote the assembly of the CARMA1-BCL10-
MALT1 complex. The IAP2-MALT1 fusion protein, which results from a chromosomal 
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translocation that is frequent in gastric MALT lymphomas, is oligomeric and 
constitutively active, and can cleave natural MALT1 substrates. In addition, the BIR 
domains of the fusion protein are able to recruit the kinase NIK, which is then 
cleaved by the active protease domain. The cleaved NIK fragment is more stable 
than full length NIK, and activates signaling events leading to NF-κB2 activation. 
Abbreviated domain names: Caspase recruitment domain (CARD), death domain 
(DD), immunoglobulin-like (Ig) domain, coiled-coil (CC) domain, membrane 
associated guanylate kinase (MAGUK) domain, baculoviral IAP repeat (BIR) domain.  
 
Figure 3 : Techniques used to monitor MALT1 activity and strategies for 
MALT1 inhibition. 
(A) The cleavage of MALT1 substrates, such as RelB shown here, leads to the 
appearance of additional faster migrating cleavage fragments detectable by Western 
Blot. (B) Incubation of MALT1 with an amc-coupled tetrapeptide substrate allows 
quantification of protease activity by release of amc, which results in a shift of the 
fluorescence emission. (C) Intracellular MALT1 activity can be measured by a FRET-
based assay, through expression of an YFP-CFP fusion protein containing a MALT1 
cleavable linker sequence. (D) Potential strategies for MALT1 inhibition: efficient 
MALT1 inhibition can be achieved by active site inhibitors, which irreversibly block 
the active site (such as MI-2), or by allosteric inhibitors that indirectly inhibit MALT1 
activity by preventing the switch to the active conformation (such as mepazine).  In 
principle there are additional means of targeting MALT1 activity, including drugs that 
would affect MALT1 dimerization or MALT1 monoubiquitination. MALT1 
monoubiquitination could be targeted by inhibition of the responsible ubiquitin ligase, 
by blocking the accessibility of the modified lysine residue or by targeting the relevant 
intra-or intermolecular ubiquitin-MALT1 interaction interface (for simplicity reasons, 
the model shows only the possibility of an intermolecular ubiquitin-MALT1 interaction 
that may stabilize the dimer).  
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References to be highlighted 
 
• Uehata et al. 
This study identifies the RNAse Regnase-1 (also known as MCPIP-1) as a substrate 
of MALT1, and shows that MALT1-dependent Regnase-1 cleavage regulates T-cell 
activation. 
 
• Pelzer et al. 
This study identifies the mechanism of MALT1 activation, which requires its 
monoubiquitination on Lysine 644, and shows that monoubiquitination of MALT1 is 
required for the growth of ABC DLBCL cell lines. 
 
•• Nagel et al. 
Together with Fontan et al., these studies identify the first small molecule MALT1 
inhibitors and show that these inhibit the growth of ABC DLBCL in a xenograft model. 
 
•• Fontan et al. 
Together with Nagel et al., these studies identify the first small molecule MALT1 
inhibitors and show that these inhibit the growth of ABC DLBCL in a xenograft model. 
 
• Rahal et al. 
By screening a panel of 16 anti-cancer drugs, this study identifies subgroups of 
mantle cell lymphomas with constitutive BCR-driven NF-κB1 activation or BCR-
independent NF-κB2 activation, and reveals constitutive MALT1 activity in the BCR-
driven subgroup.  
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